Jarrod Longcor, MS, MBA, discusses the potential utility of the small-molecule radiotherapeutic phospholipid-drug conjugate CLR 131 in patients with multiple myeloma.
Jarrod Longcor, MS, MBA
Advertisement
Articles by Jarrod Longcor, MS, MBA
Advertisement
Latest Updated Articles
The Potential Utility of CLR 131 in Multiple MyelomaFebruary 18th 2020
Advertisement
Advertisement
Trending on OncLive
1
Antibody-Drug Conjugates in Lung Cancer: The Tip of the Iceberg
2
HERIZON-GEA-01 PD-L1 Subgroup Data Support Zanidatamab Combo as a New Frontline SOC in HER2+ GEA
3
Retrospective Data Show Zanubrutinib May Less AFib Burden in Real-World CLL
4
Dato-DXd Hits Key Secondary Efficacy End Points in First-Line TNBC
5